Hims & Hers Health delivered a mixed earnings report and announced a potential Wegovy partnership with Novo Nordisk; the ...

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

In June, Novo ended a partnership with Hims & Hers that provided access to Wegovy through the pharma's Novocare Pharmacy because Hims & Hers was trying to skirt legal restrictions on compounding ...

Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, ...

Shares of Hims & Hers are trading marginally lower Monday morning, as competitive news overshadows bullish announcements from ...

Hims & Hers stock jumped 6% in post-market trading Monday after the company said it was in active discussions to make Wegovy injections and Novo Nordisk’s forthcoming obesity pill available through ...

Novo Nordisk cuts obesity drug prices to compete with Eli Lilly, offering new patient deals and nationwide access.

After a tumultuous year, a popular virtual care platform is trying its hand in a competitive blood testing market.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24 ...

CEO says company accelerating toward 2030 $6.5 billion revenue goal Talks with Novo to offer Wegovy through Hims' platform remain ongoing Revenue beat driven by core offerings - analyst Nov 3 (Reuters ...

Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added ...